NyquistAI was proud to have our CEO and Co-founder, Michelle Wu, speak as a panelist at this year’s DIA Global Labeling Conference in Arlington, Virginia. The two-day event brought together regulatory leaders, innovators, and patient advocates from around the world to explore the evolving landscape of pharmaceutical labeling — and what the future holds for technology, compliance, and patient care.

Michelle Wu on the Role of AI in Labeling

In a dynamic and forward-looking session titled “Will Artificial Intelligence (AI) Transform Drug Labeling Processes?“, Michelle Wu joined industry experts to dissect the opportunities and limitations of AI in pharmaceutical labeling.

Michelle offered a pragmatic framework for assessing where and when AI should be applied in labeling processes. “The key question isn’t just ‘Can AI do this?’ It’s ‘Do we have the data to train it — and do we know what success looks like?’” she explained. Her proposed model emphasized practical applications of AI — such as automating repetitive tasks and retrieving information from large datasets — while cautioning against overreliance in areas requiring nuance, contextual understanding, or complex judgment.

Michelle also introduced the concept of lightweight, pre-built AI “agents” that can be integrated into existing workflows with minimal disruption. This approach, she noted, offers a more accessible path to AI adoption compared to large-scale, custom-built solutions.

Her key message: “The future of pharmaceutical labeling isn’t AI vs. humans. It’s AI with humans. Together, we can drive accuracy, speed, and compliance — while keeping patient safety at the center.”

Hot Topics Across the Conference

The conference covered a wide array of subjects over its in-depth sessions, showcasing trends that are reshaping how labeling professionals operate:

• Digital and e-Labeling Innovation: Experts from Pfizer, the EMA, and the Jordan FDA explored how the FHIR ePI standard and digital leaflet readers are paving the way for personalized medicine and greater accessibility.
• Patient-Centric Labeling: Speakers emphasized co-creating labels with patients through plain language, visuals, and empathy-driven tech like chatbots—critical for improving adherence and health outcomes.
• Safety and Governance: From CCDS transition strategies to AI-driven pharmacovigilance, companies like Novartis, PepGen, and BMS shared best practices for managing safety label changes at a global scale.
• Cross-Functional Success: Leaders from Merck, Sanofi, and Gilead highlighted how mentorship, strategic alignment, and cross-functional collaboration are essential for thriving in today’s fast-paced labeling environment.
• Tech Integration and Human Factors: Eli Lilly’s case studies showcased how human-centered design and process optimization can improve device labeling, while companies like Bayer revealed lessons learned from AI implementation—both the breakthroughs and the bumps in the road.
• Labeling for Rare Disease Therapies: The final session delivered a powerful perspective on labeling for personalized therapies like CAR-T cell treatments, with insights from patients and practitioners alike.

Looking Ahead

As innovation accelerates and patient expectations evolve, conferences like DIA’s Global Labeling event are more vital than ever. They not only spark collaboration but also push the industry to embrace change thoughtfully, ethically, and effectively.

At NyquistAI, we’re proud to be part of that journey. We remain committed to building intelligent tools that support labeling professionals, empower patients, and elevate the standards of care.